Sofinnova Capital VIII 13D and 13G filings for Quince Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:29 pm Purchase |
2024-12-31 | 13G | Quince Therapeutics, Inc. QNCX |
Sofinnova Capital VIII | 2,397,711 5.400% |
242,017 (+11.23%) |
Filing |
| 2024-08-06 8:04 pm Sale |
2024-05-01 | 13G | Quince Therapeutics, Inc. QNCX |
Sofinnova Capital VIII | 2,155,694 4.990% |
-22,456 (-1.03%) |
Filing |
| 2024-02-12 09:00 am Purchase |
2023-12-31 | 13G | Quince Therapeutics, Inc. QNCX |
Sofinnova Capital VIII | 2,178,150 5.100% |
2,178,150 (New Position) |
Filing |